Home
EOLS
EOLS News

Latest Evolus Inc. (EOLS) News on October 22, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

11 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

While shareholders of Evolus (NASDAQ:EOLS) are in the black over 5 years, those who bought a week ago aren't so fortunate

Simply Wall St.

a month ago

While shareholders of Evolus (NASDAQ:EOLS) are in the black over 5 years, those who bought a week ago aren't so fortunate

When Can We Expect A Profit From Evolus, Inc. (NASDAQ:EOLS)?

Simply Wall St.

4 months ago

When Can We Expect A Profit From Evolus, Inc. (NASDAQ:EOLS)?

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 06/11/2025

Evolysse™ Recognized in 2025 Shape Skin Awards

Business Wire

4 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards

Endpoint Security Market worth $38.28 billion by 2030- Exclusive Report by MarketsandMarkets™

PR Newswire

5 months ago

Endpoint Security Market worth $38.28 billion by 2030- Exclusive Report by MarketsandMarkets™

GoNetspeed Broadens Massachusetts Network on The Cape

Business Wire

5 months ago

GoNetspeed Broadens Massachusetts Network on The Cape

PR Newswire

5 months ago

TAE Technologies Raises $150 Million in Latest Funding Round

RBC and Pattison Food Group expand partnership to bring added convenience and everyday value to shoppers in Western Canada

CNW Group

5 months ago

RBC and Pattison Food Group expand partnership to bring added convenience and everyday value to shoppers in Western Canada

AeroFlexx Awarded New Patents in Sustainable Packaging Innovation

GlobeNewswire

5 months ago

AeroFlexx Awarded New Patents in Sustainable Packaging Innovation

Crush Colossal Kaiju with a Game-Changing Blow: KAIJU NO. 8 THE GAME Unveils Details for Original Story!

PR Newswire

5 months ago

Crush Colossal Kaiju with a Game-Changing Blow: KAIJU NO. 8 THE GAME Unveils Details for Original Story!

What are Akuvox's Latest Offerings that Cement its Leadership in Smart Intercoms?

PR Newswire

5 months ago

What are Akuvox's Latest Offerings that Cement its Leadership in Smart Intercoms?

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

PR Newswire

5 months ago

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

MT Newswires

5 months ago

Evolus CFO Sandra Beaver Resigns

Evolus Announces Departure of its Chief Financial Officer

Business Wire

5 months ago

Evolus Announces Departure of its Chief Financial Officer

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Business Wire

5 months ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (EOLS): A Bull Case Theory

Insider Monkey

5 months ago

Evolus, Inc. (EOLS): A Bull Case Theory

Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Simply Wall St.

5 months ago

Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Evolus First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

5 months ago

Evolus First Quarter 2025 Earnings: Misses Expectations

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Evolus Inc Earnings Call

Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges

GuruFocus.com

5 months ago

Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges

Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates

Zacks

5 months ago

Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates

Evolus Reports First Quarter 2025 Results

Business Wire

5 months ago

Evolus Reports First Quarter 2025 Results

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Business Wire

6 months ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Zacks

6 months ago

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus to Report First Quarter Financial Results on May 7, 2025

Business Wire

6 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

BTIG Initiates Evolus at Buy With $21 Price Target

Evolus Announces Commercial Launch of Evolysse™

Business Wire

6 months ago

Evolus Announces Commercial Launch of Evolysse™

Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Business Wire

6 months ago

Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Business Wire

7 months ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain

Simply Wall St.

7 months ago

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

Evolus Insider Sold Shares Worth $1,370,249, According to a Recent SEC Filing

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas

Motley Fool

7 months ago

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Evolus Inc Earnings Call

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...

GuruFocus.com

8 months ago

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...

MT Newswires

8 months ago

Evolus Q4 Net Loss Narrows, Revenue Rises; Issues Guidance

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates

Zacks

8 months ago

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Business Wire

8 months ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?

Insider Monkey

8 months ago

Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Business Wire

8 months ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Business Wire

8 months ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Business Wire

8 months ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

Zacks

8 months ago

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

MT Newswires

8 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

8 months ago

Evolus Gets US FDA Approval for Injectable Hyaluronic Acid Gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Business Wire

8 months ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing

Simply Wall St.

8 months ago

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Zacks

9 months ago

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

Investor's Business Daily

9 months ago

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

MT Newswires

9 months ago

Evolus Reports Q4 Preliminary Net Revenue; Shares Rise Pre-Bell

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

Business Wire

9 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability

Simply Wall St.

10 months ago

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Zacks

a year ago

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Zacks

a year ago

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St.

a year ago

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Evolus Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Evolus Third Quarter 2024 Earnings: Misses Expectations

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges

GuruFocus.com

a year ago

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Zacks

a year ago

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus Reports Third Quarter 2024 Results

Business Wire

a year ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Business Wire

a year ago

Evolus to Participate in Stifel 2024 Healthcare Conference

MT Newswires

a year ago

Evolus Gains EU Approval for Estyme Hyaluronic Acid Fillers

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Business Wire

a year ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Insulet (PODD) Earnings Expected to Grow: Should You Buy?

Zacks

a year ago

Insulet (PODD) Earnings Expected to Grow: Should You Buy?

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Zacks

a year ago

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Business Wire

a year ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Business Wire

a year ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years

Simply Wall St.

a year ago

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

GuruFocus.com

a year ago

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Business Wire

a year ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?

Insider Monkey

a year ago

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Investor's Business Daily

a year ago

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Business Wire

a year ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024

Business Wire

a year ago

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Business Wire

a year ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire

a year ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues

Pharmaceutical Technology

a year ago

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues

Evolus to Report Second Quarter Financial Results on July 31, 2024

Business Wire

a year ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Business Wire

a year ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

MT Newswires

a year ago

Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Business Wire

a year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

Simply Wall St.

a year ago

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Business Wire

a year ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

GlobeNewswire

a year ago

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

Camber Energy Announces Passing of Director Lawrence Fisher

ACCESSWIRE

a year ago

Camber Energy Announces Passing of Director Lawrence Fisher

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

Newsfile

a year ago

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

CNW Group

a year ago

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

GlobeNewswire

a year ago

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

Share on Social Networks: